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traceptives, and thus UnijectTM for vaccines would need to have
distinctive distinguishing characteristics (shape, color, labeling) to
avoid negative impact on immunization programs.
Conclusion: UnijectTM has signiﬁcant advantages over tradi-
tional vaccine presentations with respect to perceptions of device
safety and efﬁcacy, reductions in waste, bundling of syringe and
needle, and time needle to vaccinate a child.While challengeswere
identiﬁed, most of these could be overcome through vaccinator
training, minor device modiﬁcations, and social mobilization.
http://dx.doi.org/10.1016/j.ijid.2014.03.1329
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Background: In 1988 the World Health Organization (WHO)
proposed mass immunization campaigns with the trivalent oral
polio vaccine (TOPV) among children less than 5 years of age. The
VaccineVialMonitor (VVM) is a small patch of heat-sensitivemate-
rial placed on the vaccine vial to register cumulative heat exposure.
A direct relationship exists between the rate at which the VVM
changes colour and ambient temperature. This in turn affects the
potency of the oral polio vaccine. [1]
Objectives: To evaluate the status of the cold chain infrastruc-
ture in Kenya and to determine the total TOPV virus concentration
of retrieved ﬁeld samples.
Methods & Materials: A stratiﬁed multi-stage sampling strat-
egy was used leading to selection of 14 health centres this study. A
total of 23TOPVvial sampleswere collected, separated into individ-
ual serotypes generating 69 samples for the potency test. Potency
of oral polio vaccine was tested using Karber’s formula. This was
then compared to the Vaccine Vial Monitor stage of the vials
Results: Our study showed that the average potency of polio
vaccine serotype1, serotype 2 and serotype 3 were as follows;
Comparison between VVM1/VVM 2 and Serotype titres calcu-
lated
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VVM
106 106.05 105 104.98 105.5 105.73 1
106 106.03 105 105.08 105.5 105.35 2
*The mean titre was calculated using the Karber’s formula[Log
CCID50 = L-d(S-0.5)]]with an allowance of +0.5 log units
Conclusion: On average the vaccine vials used in the studywere
potent with satisfactory VVM and mean serotype titre. We found
that someOPVvials haddissatisfactoryVVMstage. Vaccinepotency
was seen to be directly proportional to VVM stage of vaccine vials.
Vaccine vials kept at temperatures below -18 ◦C had a better VVM
leading to a better potency status. Some OPV Samples which had
lower titre of serotype 2 were contributed to by the temperature
of the equipment they were stored at.
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chain infrastructure in a rural district of India. Rural and Remote
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Background: Dengue is a global health problem.Platlet transfu-
sions areused in the treatment of patientswithdengue fever.Indian
guidelines promote platlet transfusions in patients with platlet
counts of less than 10,000.The main aim of our study was to deter-
mine how platlets were being used in dengue fever at a tertiary
care centre in South India.
Methods & Materials: This retrospective study was conducted
in the hospitals attached to Kasturba Medical College, Mangalore.
During the study period of one year any patientwith fever and pos-
itive IgM dengue or NS1 antigen positive was considered to have
dengue fever. Criteria for appropriate platelet transfusion was pro-
phylactic platelet transfusion for patientswithplatelet count of less
than 10000 cells per cumm or therapeutic platelet transfusion for
patients with bleeding manifestations of WHO bleeding category
III and IV.
Results: A total number of 261 dengue cases were analysed.
197 (75.48%) patients were males. The mean age of study popula-
tion was 33.74 years. Platelet transfusion was administered to 62
patients. 19 transfusions were appropriate, out of which 13 were
prophylactic and 6 were therapeutic platelet transfusions. In 43
(69.35%) patients transfusions was inappropriate.
Conclusion: Majority of platlet transfusions in our study was
inappropriate. Appropriate use of platelet concentrates should
be ensured for patients in whom it is really indicated, as it
avoids unnecessary risk of transfusion reactions and blood borne
infection.
http://dx.doi.org/10.1016/j.ijid.2014.03.1331
